J Biol Chem, Vol. 275, Issue 5, 3667-3674, February 4, 2000

Prolactin-releasing Peptide Activation of the Prolactin Promoter Is Differentially Mediated by Extracellular Signal-regulated Protein Kinase and c-Jun N-terminal Protein Kinase^*

Akiko Kimura, Masahide Ohmichi, Keiichi Tasaka, Yuki Kanda, Hiromasa Ikegami, Jun Hayakawa, Koji Hisamoto, Ken-ichirou Morishige, Shuji Hinuma^§, Hirohisa Kurachi, and Yuji Murata

From the Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan and ^§ Discovery Research Laboratories I, Pharmaceutical Discovery Research Division, Takeda Chemical Industries Ltd., 10 Wadai, Tsukuba, Ibaraki 300-4293, Japan

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Regulation of the mitogen-activated protein kinase (MAPK) family by prolactin-releasing peptide (PrRP) in both GH3 rat pituitary tumor cells and primary cultures of rat anterior pituitary cells was investigated. PrRP rapidly and transiently activated extracellular signal-regulated protein kinase (ERK) in both types of cells. Both pertussis toxin, which inactivates G_i/G_o proteins, and exogenous expression of a peptide derived from the carboxyl terminus of the -adrenergic receptor kinase I, which specifically blocks signaling mediated by the subunits of G proteins, completely blocked the PrRP-induced ERK activation, suggesting the involvement of G_i/G_o proteins in the PrRP-induced ERK activation. Down-regulation of cellular protein kinase C did not significantly inhibit the PrRP-induced ERK activation, suggesting that a protein kinase C-independent pathway is mainly involved. PrRP-induced ERK activation was not dependent on either extracellular Ca²⁺ or intracellular Ca²⁺. However, the ERK cascade was not the only route by which PrRP communicated with the nucleus. JNK was also shown to be significantly activated in response to PrRP. JNK activation in response to PrRP was slower than ERK activation. Moreover, to determine whether a MAPK family cascade regulates rat prolactin (rPRL) promoter activity, we transfected the intact rPRL promoter ligated to the firefly luciferase reporter gene into GH3 cells. PrRP activated the rPRL promoter activity in a time-dependent manner. Co-transfection with a catalytically inactive form of a MAPK construct or a dominant negative JNK, partially but significantly inhibited the induction of the rPRL promoter by PrRP. Furthermore, co-transfection with a dominant negative Ets completely abolished the response of the rPRL promoter to PrRP. These results suggest that PrRP differentially activates ERK and JNK, and both cascades are necessary to elicit rPRL promoter activity in an Ets-dependent mechanism.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Prolactin (PRL)¹ is important in pregnancy and lactation in mammals, and is involved in the development of the mammary glands and the promotion of milk synthesis (1). Thyrotropin-releasing hormone (TRH) is a physiological regulator of pituitary cell function that stimulates prolactin synthesis and secretion (2). Recently, a new peptide which is a ligand of the "orphan" receptor hGR3 expressed specifically in the human pituitary was identified in the hypothalamus as a potent prolactin-releasing factor for rat anterior pituitary cells (3). This peptide was named "prolactin-releasing peptide" (PrRP).

The receptor of PrRP, hGR3, is referred to as a seven-transmembrane domain receptor or a G protein-coupled receptor (4, 5). Although it was reported that PrRP induced arachidonic acid metabolite release as well as PRL secretion (3), the signal transduction pathway in PrRP-induced PRL secretion or synthesis has remained unknown. The effects of TRH are presumably mediated by activation of phosphatidylinositol 4,5-bisphosphate-phospholipase C, leading to the production of inositol phosphates and diacylglycerol (6, 7). Indeed, many of the downstream effects of TRH are believed to be dependent on mobilization of intracellular calcium and activation of protein kinase C (PKC). Although G protein-coupled receptors are thought to be linked primarily to second messenger systems, protein tyrosine phosphorylation can occur soon after receptor occupancy in some cases (8, 9).

Intracellular transmission of extracellular signals is mediated in large part by several groups of sequentially activated protein kinases, which are collectively known as the mitogen-activated protein kinase (MAPK) cascades. In growth factor signaling, the key elucidated MAPK cascade is that involving the extracellular signal-regulated kinase (ERK). Recent evidence indicates that some G protein-coupled receptors can activate the ERK cascade (10-12). The signals transmitted through the ERK cascade lead to activation of a set of regulatory molecules that ultimately initiate cellular responses such as growth and differentiation (13-15). Recently we have shown that TRH is capable of activating ERK in pituitary organ culture (16) and in GH3 rat pituitary tumor cells (10), and that ERK might be involved in PRL secretion or synthesis (17). However, the ERK cascade is not the only link between membrane receptors and their intracellular targets, and several other ERK-like cascades have been identified (18). One of the most studied of these cascades is the Jun N-terminal kinase (JNK: also known as stress-activated protein kinase (SAPK) (19, 20)) cascade, which is activated in response to cellular stresses such as apoptosis (19, 21). ERK, JNK, and p38 (22) are members of the MAPK family. Recent data indicate that GnRH is capable of activating ERK (23, 24), JNK (25), and p38 (26) in the T3-1 gonadotroph cell line.

It has been shown that Raf, ERK, and Ets are crucial components of the downstream transmission of the Ras signal in the regulation of the PRL promoter activity (27, 28). The Ets family of transcription factors, which comprises a number of phosphoproteins with a conserved DNA-binding motif named the Ets domain (29), have been demonstrated to be phosphorylated and activated by ERK (30). Several Ets-binding sites have been identified in the proximal PRL promoter.

Taken together, these facts led us to examine whether PrRP stimulates the activity of ERK or JNK, and whether each of these cascades plays a role in the transcriptional activation of the rat PRL (rPRL) gene in GH3 cells.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Materials-- Phorbol 12-myristate 13-acetate (PMA) and myelin basic protein were purchased from Sigma. PrRP was a gift from Takeda Chemical Industries Ltd. (Japan). ECL Western blotting detection reagents were obtained from Amersham Pharmacia Biotech. [-³²P]ATP (3000 Ci/mmol) was obtained from NEN Life Science Products Inc. Erk1 rabbit polyclonal anti-ERK antiserum and monoclonal antibody 9E10 to the Myc epitope were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). PD98059 and the SAPK/JNK assay kit, including the NH₂-terminal c-Jun fusion protein bound to glutathione-Sepharose beads and a phospho-specific c-Jun antibody (Ser⁶³), were obtained from New England Biolabs (Beverly, MA).

Cell Cultures-- GH3 cells were cultured at 37 °C in DMEM containing 10% fetal bovine serum in a water-saturated atmosphere of 95% O₂ and 5% CO₂. The preparation of cultured pituitary cells was described previously (31). Briefly, female Wistar rats (200-250 g) were decapitated and their anterior pituitary glands were quickly removed and placed in DMEM containing 10% fetal bovine serum. The anterior lobes were cut into 1-mm³ pieces with a scalpel. The tissue fragments were exposed to 20 µg/ml trypsin (Sigma, type 3) for 25 min at 37 °C and centrifuged (200 × g, 5 min). Then they were exposed to 2.5 µg/ml pancreatin (Life Technologies, Inc., Grand Island, NY) for 15 min at 37 °C, centrifuged (200 × g, 5 min) and resuspended in DMEM. The tissue blocks were disrupted by pipetting them in plastic pipettes with tapering tips until a single-cell suspension was obtained. Then the cells were centrifuged and washed to remove extracellular trypsin and pancreatin. They were then suspended in DMEM containing 10% fetal bovine serum, seeded into 100-mm dishes, and incubated for 4 days in a humidified atmosphere of 95% O₂ and 5% CO₂ at 37 °C to allow them to become attached to the dishes.

Construction of Expression Plasmids-- Myc-tagged p42^mapk expression plasmid (pEXV-Erk2-tag) was obtained from Dr. C. J. Marshal (Institute of Cancer Research, London, United Kingdom) (32). The ARKct peptide-encoding minigene, containing cDNA encoding the carboxyl-terminal 195 amino acids of ARK1, was prepared as described previously (33). The reporter construct pA3-425PRLluc (34-36) contains a 498-base pair fragment encompassing positions 425 to +73 of the rPRL gene ligated upstream of the luciferase reporter gene in pA3luc (37), and contains three polyadenylation sites. The reporter construct pA3-425PRLluc and the plasmid pLNCX-MAPK (K  M) (37) were kind gifts from Dr. A. Gutierrez-Hartmann (University of Colorado Health Sciences Center, Denver, CO). Plasmids encoding Ets-2 and its dominant negative form (38) were kind gifts from Dr. K. E. Boulukos (Center de Biochimie, Faculté des Sciences, Nice, France). pAPr-etsZ, encoding the consensus DNA-binding domain of Ets-2, was a kind gift from Dr. M. Ostrowski (Ohio State University, Columbus) (39). The plasmid encoding the dominant negative c-Jun (dnJun), pLHCc-Jun (S63A, S73A) (40), was a kind gift from Dr. D. Mercola (University of California, San Diego). The plasmid encoding the dominant negative SAPK/JNK (pcDL-SR-SAPK-VPF) was a kind gift from Dr. E. Nishida (Kyoto University, Kyoto, Japan) (41).

Assay of ERK Activity-- Cells were incubated overnight in the absence of serum and then treated with various substances. They were then washed twice with phosphate-buffered saline and lysed in ice-cold HNTG buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EDTA, 10 mM sodium pyrophosphate, 100 µM sodium orthovanadate, 100 mM sodium fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) (42). The extracts were centrifuged to remove cellular debris, and the protein content of the supernatants was determined using the Bio-Rad protein assay reagent (Bio-Rad). Erk1 rabbit polyclonal antibody was bound to protein A-Sepharose beads, and 300 µg of protein from the lysate samples was immunoprecipitated at 4 °C for 2 h. The immunoprecipitated products were washed once in HNTG buffer, twice in 0.5 M LiCl, 0.1 M Tris, pH 8.0, and once in kinase assay buffer (25 mM HEPES, pH 7.2-7.4, 10 mM MgCl₂, 10 mM MnCl₂, and 1 mM dithiothreitol), and samples were resuspended in 30 µl of kinase assay buffer containing 10 µg of myelin basic protein and 40 µM [-³²P]ATP (1 µCi) as described previously (23). The kinase reaction was allowed to proceed at room temperature for 5 min and stopped by the addition of Laemmli SDS sample buffer (43). Reaction products were resolved by 15% SDS-PAGE.

Assay of 42-kDa ERK Activity Using a Transient Expression System-- GH3 cells cultured in 100-mm dishes were transfected with Myc-tagged p42^mapk expression plasmid (1 µg of pEXV-Erk2-tag) in combination with 9 µg of pRK or pRK-ARK1 using LipofectAMINE as described previously (12, 44). At 72 h after transfection, serum-deprived cells were incubated with 1 µM PrRP for 5 min, and expressed Myc-tagged p42^mapk was immunoprecipitated with 1 µg of antibody 9E10. The ERK activity in the immunoprecipitate was measured as described above. The transfection efficiency of each experiment was 8-10% as assessed by -galactosidase staining after transfection of a -galactosidase-containing expression plasmid.

Assay of JNK Activity-- JNK activity was precipitated from 250 µg of whole cell lysates by incubation with 2 µg of GST-cJun (1-89) fusion protein/GSH-Sepharose beads for 18 h at 4 °C (New England BioLabs) (20). c-Jun (1-89) contains a high-affinity binding site for JNK close to the NH₂-terminal: this site contains two phosphorylation sites at Ser⁶³ and Ser⁷³. The beads were washed and resuspended in 50 µl of kinase buffer containing 100 µM ATP for 30 min at 30 °C as described (45). The solid-phase kinase reaction was terminated by addition of Laemmli sample buffer, and phosphorylation of GST-cJun on Ser⁶³ was examined after SDS-PAGE and immunoblotting with anti-phospho(Ser⁶³) c-Jun antibody.

rPRL Promoter Assay-- GH3 cells cultured in 24-well plates were transfected with pA3-425PRLluc and CMV--galactosidase plasmid (to normalize for cell viability and transfection efficiency) in combination with the indicated plasmids using LipofectAMINE. At 48 h after transfection, serum-deprived cells were incubated with 1 µM PrRP for the indicated times. In some of the experiments, cells were treated with 20 µM PD98059 for 15 min before the addition of 1 µM PrRP. Cell extracts were prepared by lysing the cells with three sequential freeze-thaw cycles in a buffer containing 100 mM potassium phosphate, pH 7.8, and 10 mM dithiothreitol. Vigorous vortexing was used to enhance cell lysis. Unlysed cells and insoluble material were pelleted at 10,000 rpm for 10 min at 4 °C. The supernatant volume was measured, and aliquots of the supernatant were used in the subsequent luciferase and -galactosidase assays.

Luciferase was assayed as described previously (34). Briefly, the luciferase assay mixture contained 100 mM KPO₄, pH 7.8, 1 mM dithiothreitol, 3.7 mM MgSO₄, 530 µM ATP, and 470 µM luciferin plus 20 µl of cell extract in a final volume of 100 µl. Luciferin was added just before measuring light units, which were measured in duplicate during the first 40 s of the reaction at 25 °C in a Luminometer (46).

-Galactosidase was assayed as described previously (34). The -galactosidase buffer contained 60 mM sodium phosphate, pH 7.5, 1 mM MgCl₂, 0.80 mg/ml o-nitrophenyl---galactopyranoside, and 40 mM -mercaptoethanol. A standard curve containing 100 microunits to 2 milliunits of -galactosidase was made with each assay. A 30-µl aliquot of cell extract was incubated with assay buffer until color developed (30-120 min), and the reaction was then stopped by adding Na₂CO₃ to a final concentration of 625 mM. Absorbance was then read at 405 nm.

Luciferase light units were normalized relative to the activity of -galactosidase. The control value was then set at 1 and the data expressed as fold-stimulation relative to control. Data are expressed as the mean ± S.E.

Statistics-- Statistical analysis was performed by Student's t test, and p < 0.01 was considered significant. Data are expressed as the mean ± S.E.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

PrRP Stimulation of ERK Activity-- Recently we reported that the activity of ERK is stimulated by TRH in GH3 cells (10). TRH is a potent factor that is known to be capable of promoting both PRL secretion and synthesis (2). PrRP was comparable to TRH in its potency (3). PrRP acts through a specific receptor, which is referred to as a seven-transmembrane domain receptor or G protein-coupled receptor (4, 5). We therefore investigated whether PrRP might induce the activation of ERK. GH3 cells were treated with 1 µM PrRP for the indicated times. Cell lysates were immunoprecipitated with anti-ERK antibody and examined for ERK activity by assaying the incorporation of ³²P into MBP, followed by SDS-PAGE and autoradiography (Fig. 1A). PrRP produced an increase in this kinase activity within 2.5 min, with a maximum at 5 min and a decline thereafter. The dose dependence of PrRP-induced ERK activation was also evaluated (Fig. 1B). The GH3 cells were treated with various concentrations of PrRP for 5 min. Activation of ERK was clearly detected with 10⁸ M PrRP and was maximal at 10⁶ M (Fig. 1B). The doses of PrRP that stimulated ERK activity were similar to those which stimulate the release of PRL (3).

View larger version (34K): [in this window] [in a new window]   Fig. 1.   The effect of PrRP on the activity of ERK. GH3 cells were grown in 100-mm dishes. A, in the left panel, cells were treated with 1 µM PrRP for the indicated times (lanes 2-5) or 1 nM epidermal growth factor (lane 6) for 5 min. In the right panel, cells were treated with 1 µM PrRP for 5 min (lane 2) or 3 h (lane 3). B, cells were treated with the indicated concentrations of PrRP for 5 min. Lysates of cells were subsequently immunoprecipitated (I.P.) with anti-ERK antiserum, and the immunoprecipitates were incubated with [-32P]ATP in the presence of MBP, as described under "Experimental Procedures." After the reactions were stopped with Laemmli sample buffer, samples were subjected to SDS-PAGE and autoradiography. Autoradiograms of 32P-labeled MBP are shown in the lower panel. Relative densitometric units of the MBP bands are shown in the upper panel, with the density of the control bands set arbitrarily at 1.0. Values shown represent the mean ± S.E. from at least three separate experiments. ** indicates p < 0.01 as compared with the control.

G-mediated PrRP-induced ERK Activation-- It has been shown that the receptors for both TRH (6, 7) and PrRP (4, 5) are members of the superfamily of G protein-coupled receptors. We compared the mechanisms of ERK activation induced by each TRH and PrRP. To determine what type of G protein is coupled to each receptor, we pretreated GH3 cells (Fig. 2A, left panel) or primary cultures of rat anterior pituitary cells (Fig. 2A, right panel) with 100 ng/ml pertussis toxin (PTX) for 4 h in order to inactivate G_i and G_o proteins, and then treated the cells with 1 µM PrRP or TRH for 5 min. Although PTX at 100 ng/ml almost completely blocked the PrRP-induced ERK activation (Fig. 2A, lane 4), PTX did not have an apparent effect on TRH-induced ERK activation (Fig. 2A, lane 6) in both types of cells. Thus, the effect of PrRP on ERK activity involves PTX-sensitive G proteins such as G_i or G_o, whereas that of TRH does not involve PTX-sensitive G proteins.

View larger version (31K): [in this window] [in a new window]   Fig. 2.   G-mediated PrRP-induced ERK activation. A, GH3 cells grown in 100-mm dishes (left panel) or primary cultures of rat anterior pituitary cells in 100-mm dishes (right panel) were pretreated with 100 ng/ml PTX for 4 h (lanes 2, 4, and 6), and then treated with 1 µM PrRP (lanes 3 and 4) or 1 µM TRH (lanes 5 and 6) for 5 min. Lysates of cells were subsequently immunoprecipitated (I.P.) with an anti-ERK antiserum, and the immunoprecipitates were incubated with [-32P]ATP in the presence of MBP, as described under "Experimental Procedures." After the reactions were stopped with Laemmli sample buffer, SDS-PAGE and autoradiography were performed. Autoradiograms of 32P-labeled MBP are shown in the lower panel. B, cells were transfected with pRK (lanes 1 and 2) or pRK-ARK1 (lanes 3 and 4) together with Myc-tagged p42mapk expression plasmid (pEXV-Erk2-tag) and, after 72 h, were stimulated with 1 µM PrRP (lanes 2 and 4). Autoradiograms of ERK activity immunoprecipitated with antibody to the Myc epitope and assayed by 32P incorporation into MBP are shown in the lower panel. Relative densitometric units of the MBP bands is shown in the upper panel, with the density of the control bands set arbitrarily at 1.0. Values shown represent the mean ± S.E. from at least three separate experiments. Significant differences are indicated by asterisks. **, p < 0.01.

It has been reported that the carboxyl terminus of the -adrenergic receptor kinase, containing its G-binding domain, is a cellular G antagonist capable of specifically distinguishing G- and G-mediated processes (33). To examine the effect of the G subunit-sequestrant ARKct peptide on PrRP-induced exogenous ERK activity, a Myc-tagged p42^mapk expression plasmid was used to distinguish exogenous ERK from endogenous ERK. We transfected cells with pRK or pRK-ARK1 together with a Myc-tagged p42^mapk expression plasmid (pEXV-Erk2-tag) and after 72 h stimulated them with 1 µM PrRP for 5 min (Fig. 2B). Cell lysates were immunoprecipitated with antibody to the Myc epitope and examined for the exogenous ERK activity by assaying the incorporation of ³²P into MBP, and the level of phosphorylation was normalized relative to the amount of Myc-tagged p42^mapk. Transfection with pRK-ARK1 completely abolished the PrRP-induced ERK activation in GH3 cells (Fig. 2B, lane 4). These results suggest that ERK activation by PrRP is mediated by G in GH3 cells.

Role of PKC in Activation of ERK-- Many G protein-linked receptors can mediate stimulation of ERK activity via the phospholipase C-dependent activation of PKC (47, 48). Activation of ERK by TRH requires PKC in GH3 cells (10). Therefore, the role of PKC in PrRP-induced ERK activation was examined (Fig. 3). Exposure of GH3 cells to PMA caused a stimulation of ERK activity (Fig. 3, lane 6). However, the ability of PMA to induce the activation of ERK does not necessarily mean that the PKC pathway is involved in PrRP-induced ERK activation, as in the case of norepinephrine-induced ERK activation in both adipocytes (49) and GT-1 GnRH neuronal cell lines (50). Whether PKC is indeed involved in PrRP signaling was determined using PKC depletion. Pretreatment with 1 µM PMA for 16 h to deplete most PKC isoforms partially attenuated the PrRP- (Fig. 3, lane 3) and completely abolished the TRH- (Fig. 3, lane 5) induced ERK activation. These results suggest that activation of ERK by TRH is mainly mediated by PKC and activation of ERK by PrRP is partly mediated by PKC.

View larger version (18K): [in this window] [in a new window]   Fig. 3.   The effect of the down-regulation of PKC on PrRP-induced ERK in GH3 cells. Cells grown in 100-mm dishes were incubated with (lanes 3 and 5) or without (lanes 1, 2, 4, and 6) 1 µM PMA for 16 h and then treated with 1 µM PrRP for 5 min (lanes 2 and 3), or 1 µM TRH for 5 min (lanes 4 and 5), or 1 µM PMA for 10 min (lane 6). Lysates of cells were assayed for ERK activity as described in the legend for Fig. 1. An autoradiogram of 32P-labeled MBP is shown in the lower panel. The relative densitometric units of the MBP bands are shown in the upper panel with the density of the control bands set arbitrarily at 1.0. Values shown represent the mean ± S.E. from at least three separate experiments. Significant differences are indicated by asterisks. **, p < 0.01.

Role of Extracellular and Intracellular Ca²⁺ in ERK Activation-- It has been reported that Ca²⁺ influx is important as a signal-transduction pathway in PRL secretion by pituitary cells (51) and that PrRP could induce Ca²⁺ influx (3). We therefore evaluated the effect of Ca²⁺ influx on the PrRP- and TRH-induced ERK activation (Fig. 4A). Elimination of extracellular Ca²⁺ by treatment with 3 mM EGTA for 1 min completely blocked the TRH-induced ERK activation (Fig. 4A, lane 7), indicating that Ca²⁺ influx is required for TRH-induced ERK activation. Interestingly, neither elimination of extracellular calcium by treatment with 3 mM EGTA for 1 min nor elimination of both extracellular and intracellular Ca²⁺ by treatment with 3 mM EGTA for 15 min (52) attenuated the PrRP-induced ERK activation (Fig. 4A, lanes 3 and 4). Moreover, treatment with 50 µM BAPTA-AM for 20 min to eliminate intracellular Ca²⁺ had no effect on PrRP-induced ERK activation (Fig. 4A, lane 5). Next, the effect of extracellular and intracellular Ca²⁺ on PrRP-induced ERK activation was examined in primary cultures of rat anterior pituitary cells (Fig. 4B). Incubation in calcium-free medium, elimination of extracellular Ca²⁺ by treatment with 3 mM EGTA for 1 min, and elimination of intracellular Ca²⁺ by treatment with 50 µM BAPTA-AM for 20 min had no effect on PrRP-induced ERK activation. These results suggest that TRH-induced ERK activation is completely dependent on extracellular Ca²⁺, whereas PrRP-induced ERK activation is dependent on neither extracellular Ca²⁺ nor intracellular Ca²⁺.

View larger version (32K): [in this window] [in a new window]   Fig. 4.   Lack of a role of Ca2+ in the activation of ERK by PrRP. A, GH3 cells were grown in 100-mm dishes. Cells were pretreated with 3 mM EGTA for 1 min (lanes 3 and 7) or 15 min (lane 4), or with 50 µM BAPTA-AM for 20 min (lane 5), and then treated with 1 µM PrRP (lanes 2-5) or 1 µM TRH (lanes 6 and 7) for 5 min. B, primary cultures of rat anterior pituitary cells were grown in 100-mm dishes. Cells were changed to Ca2+-free medium by washing with calcium-free Hanks' solution, followed by placement of 10 ml of calcium-free Hanks' solution in the plates (lane 3). Cells were pretreated with 3 mM EGTA for 1 min (lane 4), or 50 µM BAPTA-AM for 20 min (lane 5), and then treated with 1 µM PrRP (lanes 2-5) for 5 min. The activity of ERK was measured as described in the legend for Fig. 1. Autoradiograms of 32P-labeled MBP are shown in the lower panel. Relative densitometric units of the MBP bands are shown in the upper panel, with the density of the control bands set arbitrarily at 1.0. Values shown represent the mean ± S.E. from at least three separate experiments.  indicates p < 0.01 as compared with TRH treatment. ** indicates p < 0.01 as compared with the control.

Stimulation of JNK Activity by PrRP and TRH-- To determine whether JNK activity was affected by PrRP or TRH, we used a GST-cJun (1-89) fusion protein bound to GSH-Sepharose beads to precipitate the JNK activity from GH3 cell lysates. The precipitated complex was subjected to an in vitro solid-phase kinase assay, and then phosphorylation on Ser⁶³ was measured by Western blotting with anti-phospho(Ser⁶³) c-Jun antibody. JNK activity was clearly stimulated by both PrRP (Fig. 5A, left panel) and TRH (Fig. 5A, right panel). JNK activation was detected 5 min after the initiation of the PrRP or TRH treatment, it peaked by 3 h, and decreased over the next 16 h. Thus, JNK activation by PrRP was slower than its ERK activation (Fig. 1A). Next, we examined the effect of PTX on the PrRP-induced JNK activation. Pretreatment with 100 ng/ml PTX for 4 h did not completely inhibit the PrRP-induced JNK activation (Fig. 5B, lane 3), which was different from the effect of PTX on the PrRP-induced ERK activation (Fig. 2A). In addition, the role of PKC in the PrRP-induced JNK activation was examined. Pretreatment with 1 µM PMA for 16 h significantly inhibited the PrRP-induced JNK activation (Fig. 5B) as was also true for the PrRP-induced ERK activation (Fig. 3, lane 3).

View larger version (24K): [in this window] [in a new window]   Fig. 5.   The effect of PrRP on the activity of JNK. GH3 cells were grown in 100-mm dishes. A, cells were treated with 1 µM PrRP (left panel) or 1 µM TRH (right panel) for the indicated times (lanes 2-5). B, cells were pretreated with 100 ng/ml PTX for 4 h (lane 3) or 1 µM PMA for 16 h, and then treated with 1 µM PrRP for 3 h (lanes 2-4). Lysates of cells were subsequently incubated with GST-cJun fusion protein/GSH-Sepharose beads followed by SDS-PAGE and Western blot analysis with anti-phospho (Ser63) c-Jun antibody, as described under "Experimental Procedures." Autoradiograms of phosphorylated GST-cJun are shown in the lower panel. Relative densitometric units of the phosphorylated GST-cJun bands are shown at the upper panel, with the density of the control bands set arbitrarily at 1.0. Values shown represent mean ± S.E. from at least three separate experiments.  indicates p < 0.01 as compared with PrRP treated. ** indicates p < 0.01 as compared with control.

Stimulation of PRL Promoter Activity by PrRP-- We sought to determine whether the ERK and/or JNK cascades are involved in the regulation of PRL synthesis induced by PrRP. A rat PRL (rPRL) promoter (425 base pairs)-luciferase reporter construct was transiently transfected into GH3 cells. As shown in Fig. 6A, addition of 1 µM PrRP enhanced the luciferase activity in a time-dependent fashion, reaching a plateau (6.2-fold) at 12 h. To examine whether the stimulation of the rPRL promoter by PrRP is the result of activation of the ERK cascade, either PD98059, an inhibitor of MEK, or an expression vector, pLNCX-MAPK (K  M), encoding a catalytically inactive form of MAPK (iMAPK) was used. PD98059 is relatively specific for MEK, with no inhibitory activity against a number of other serine/threonine and tyrosine kinases (53, 54). Pretreatment with PD98059 (20 µM) and co-transfection with pLNCX-MAPK (K  M) significantly attenuated the PrRP-induced rPRL promoter activation (Fig. 6B). These results suggest that the ERK cascade is involved in the PrRP-induced rPRL promoter activation. We next examined the possibility of the involvement of the JNK cascade in the stimulation of the rPRL promoter by PrRP. An expression plasmid that encodes a dominant negative SAPK/JNK (pcDL-SR-SAPK-VPF) was used to inhibit the JNK cascade (41). Co-transfection with pcDL-SR-SAPK-VPF significantly attenuated the PrRP-induced rPRL promoter activation (Fig. 6B), suggesting that the JNK cascade is also involved in the PrRP-induced rPRL promoter activation.

View larger version (30K): [in this window] [in a new window]   Fig. 6.   Stimulation of the rPRL promoter activity by PrRP through ERK and JNK cascades. A, GH3 cells were transiently co-transfected with 0.4 µg of the reporter construct pA3-425PRLluc and 0.04 µg of an internal control, pCMVgal. After transfection, cells were treated with 1 µM PrRP for the indicated times prior to harvesting. B, GH3 cells were transiently co-transfected with 0.4 µg of the reporter construct pA3-425PRLluc and 0.04 µg of an internal control, pCMVgal, with or without 1.2 µg of iMAPK vector (pLNCX-MAPK (K  M)) or 1.2 µg of pcDL-SR-SAPK-VPF, as indicated. After transfection, cells were incubated with or without 20 µM PD98059 for 15 min as indicated, and then treated with 1 µM PrRP for 12 h prior to harvesting. Luciferase activity was normalized relative to -galactosidase activity, and the basal activity of pA3-425PRLluc was set at 1.0. Data are expressed as the mean fold activation ± S.E. of six transfections. ** indicates p < 0.01 as compared with control.

An Ets Transcription Factor Is a Nuclear Acceptor of the MAPK Family Signaling Cascade-- Members of the recently characterized Ets transcription factor family contain a transactivation domain at the amino terminus and a highly conserved DNA-binding domain at the carboxyl terminus, and this latter domain defines the Ets family of transcription factors since it lacks homology to other DNA-binding motifs (55). Members of the ternary complex factor subfamily of Ets transcription factors are also targets of MAP kinase cascades (56). The Ets-domain transcription factor Elk-1 is a substrate for three distinct classes of MAP kinase family members (56-58). In addition, previous studies from other laboratories have suggested that Ets transcription factors mediate the response of the PRL gene to Ras (27, 28), insulin (59, 60), insulin-like growth factor-1 (61), and fibroblast growth factor (62). Therefore, these findings led us to examine whether Ets transcription factors are the nuclear acceptors for PrRP signaling. To examine the functional role of Ets transcription factors in PrRP-induced activation of the rPRL promoter, the effect of an expression plasmid that encodes a dominant negative Ets construct (pAPr-etsZ) was examined. The pAPr-etsZ construct encodes the highly conserved DNA-binding domain of c-Ets-2 protein devoid of the transactivation domain, and inhibits the effects of both Ets-1- and Ets-2-mediated responses (39) since Ets-1 and Ets-2 recognize the same DNA sequence motif (39, 55). Co-transfection with pAPr-etsZ completely blocked PrRP-induced transcriptional stimulation (Fig. 7A). Moreover, we examined the effect of an expression plasmid that encoded a truncated Ets-2 with a dominant negative activity (pRK5-ets-21-328). Co-transfection with pRK5-ets-21-328 also completely blocked PrRP-induced transcriptional stimulation (Fig. 7B). In contrast, co-transfection with an ets-2 expression plasmid (pRK5-ets-2) did not have an apparent effect on the PrRP-induced rPRL promoter activation (Fig. 7B). Thus, the inhibitory effect of pRK5-ets-21-328 on the PrRP-induced rPRL promoter activation appeared to be due to interference with activated Ets-2. These results suggest that a member of the Ets transcription factor family is a nuclear acceptor for the stimulation of rPRL promoter activity by PrRP.

View larger version (39K): [in this window] [in a new window]   Fig. 7.   Dominant-negative Ets inhibits PrRP activation of the rPRL promoter. GH3 cells were transiently co-transfected with 0.4 µg of the reporter construct pA3-425PRLluc and 0.04 µg of an internal control, pCMVgal, with or without 1.2 µg of pAPr or pAPr-etsZ (A) or 1.2 µg of pRK5, pRK5-ets-21-328, or pRK5-ets-2 (B), as indicated. After transfection, cells were treated with 1 µM PrRP for 12 h prior to harvesting. Luciferase activity was normalized relative to -galactosidase activity, and the basal activity of pA3-425PRLluc was set at 1.0. Data are expressed as the mean fold activation ± S.E. of six transfections. ** indicates p < 0.01 as compared with the respective control.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

PrRP was isolated as the ligand of an "orphan receptor," which is a seven-transmembrane domain receptor specifically expressed in the pituitary (3). PrRP induced arachidonic acid metabolite release as well as PRL secretion in both primary cultured rat anterior pituitary cells and a rat pituitary adenoma-derived cell line, RC-4B/C (3). Since TRH is a potent factor capable of promoting both PRL secretion and synthesis (2), we considered the possibility that PrRP can also act on PRL synthesis as well as PRL release. We reported previously that TRH rapidly and transiently induced ERK activation (10, 16). PrRP was almost as potent as TRH in the ability to induce ERK activation in both GH3 cells and primary cultured rat anterior pituitary cells (Fig. 2A). It is well known that either extracellular Ca²⁺ or intracellular Ca²⁺ is involved in the induction of PRL secretion by TRH (51). Although PrRP could induce Ca²⁺ influx in CHO-19P2 cells (3), PrRP-induced ERK activation was not dependent on either extracellular or intracellular Ca²⁺ in GH3 cells (Fig. 4A) or in primary pituitary cultures (Fig. 4B). In addition, the time frame of PrRP-induced ERK activation (Fig. 1A) was not as rapid as that of PrRP-induced intracellular Ca²⁺ mobilization (data not shown). These facts led us to examine the effect of PrRP on PRL synthesis and the role of the ERK cascade in PRL synthesis. PrRP activated rPRL promoter activity in a time-dependent fashion (Fig. 6A). Either pretreatment with PD98059 or co-transfection with an iMAPK-encoding construct to block the ERK cascade significantly inhibited PrRP-induced rPRL promoter activation. These data suggest that the ERK cascade might be involved in the PrRP-induced PRL synthesis.

Distinct pathways of G_i- and G_q-mediated ERK activation have been reported (33). The activation of G_i-coupled receptors, such as thrombin (63), oxytocin (11), prostaglandin F2 (12), and endothelin-1 (44), appears to be PTX-sensitive and PKC-independent. In addition, G_i-mediated ERK activation is initiated by phosphatidylinositol 3-kinase activity, followed by a pathway common to tyrosine kinase receptors (64). However, in the case of receptors that couple to G_q, such as bombesin, activation is thought to be secondary to stimulation of phosphatidylinositol 4,5-bisphosphate-phospholipase C, leading to production of inositol phosphate and diacylglycerol, with subsequent PKC-mediated stimulation of ERK (47). TRH binds to a G protein-coupled receptor, presumably of the PTX-insensitive G_q family, and activates multiple signaling pathways in pituitary cells (10). In this study, pretreatment with PTX did not apparently block the TRH-induced ERK activation (Fig. 2A) and apparent down-regulation of PKC by prolonged incubation with PMA attenuated the stimulation of ERK activity by TRH (Fig. 3), confirming the involvement of PTX-insensitive G_q-protein kinase C in TRH-induced ERK activation. On the other hand, both pretreatment with PTX and expression of ARK1 blocked the PrRP-induced ERK activation (Fig. 2) and down-regulation of PKC by prolonged incubation with PMA did not apparently attenuate the stimulation of ERK activity by PrRP (Fig. 3), suggesting that PrRP stimulation of ERK activity is not likely to be mainly mediated by G_q-protein kinase C, but to be mediated by a PTX-sensitive G protein (G_i or G_o).

Ca²⁺ is a critical mediator of the induction of PRL secretion by TRH in both primary cultures of rat anterior pituitary cells (51) and GH3 cells (65). In addition, the regulation of the PRL promoter by TRH is dependent on Ca²⁺ influx (66). Elimination of extracellular Ca²⁺ by treatment with 3 mM EGTA for 1 min completely abolished the TRH-induced ERK activation (Fig. 4A). On the other hand, elimination of extracellular Ca²⁺ by treatment with 3 mM EGTA for 1 min (Fig. 4), extracellular Ca²⁺ and intracellular Ca²⁺ by treatment with 3 mM EGTA for 15 min (Fig. 4A), or intracellular Ca²⁺ by treatment with 50 µM BAPTA-AM for 20 min (Fig. 4) did not attenuate PrRP-induced ERK activation. These results also confirmed that the mechanism of PrRP-induced ERK activation might be different from that of TRH-induced ERK activation.

One important downstream biochemical event that occurs after ligand binding to many growth-promoting receptors is the activation of members of the MAP kinase family, including ERK and JNK (22). The existence of parallel cascades leading to activation of either ERK or JNK was reported. PrRP induced the activation of both ERK and JNK. Is the mechanism of PrRP-induced ERK activation different from that of PrRP-induced JNK activation? PrRP activated ERK in a partly PKC-dependent, extracellular and intracellular Ca²⁺-independent manner (Figs. 3 and 4). Since EGTA itself induced JNK activation in GH3 cells (data not shown), the effect of EGTA on PrRP-induced JNK activation could not be examined. PrRP activated JNK in a PKC-dependent manner (Fig. 5B). Interestingly, although PTX completely inhibited the PrRP-induced ERK activation (Fig. 2), PTX only partially inhibited the PrRP-induced JNK activation (Fig. 5B). Moreover, the time course of the JNK activation (Fig. 5A) in response to PrRP was slower than that of ERK activation (Fig. 1A). Thus, the regulation of the JNK activation by PrRP appeared to be different from that of the ERK activation.

PrRP-induced activation of the rPRL promoter was attenuated by either pretreatment with MEK inhibitor PD98059 or co-transfection with an iMAPK construct (Fig. 6B), suggesting the requirement of the ERK cascade for the PrRP-induced rPRL promoter activation. Since PrRP-induced transcription of the rPRL gene was not fully blocked by either pretreatment with PD98059 or co-transfection with an iMAPK construct, it is likely that intracellular cascades other than the ERK cascade are also involved in transducing the transcriptional effects of PrRP. Since JNK activity was also stimulated by PrRP (Fig. 5), there is a possibility that the JNK cascade is also involved in the PrRP-induced rPRL promoter activation. PrRP-induced activation of the rPRL promoter was attenuated by co-transfection with a dominant negative SAPK/JNK construct (Fig. 6B), suggesting the requirement of the JNK cascade for the PrRP-induced rPRL promoter activation.

Transcription factors binding to a PrRP-responsive region of the rPRL promoter have not been identified. ERKs have been reported to phosphorylate the ternary complex factor Elk-1, which controls the expression of the c-fos gene (67, 68). It has been demonstrated that JNK phosphorylates c-Jun and ATF-2 at the putative regulatory amino-terminal serine residues and increases their transcriptional activities (19, 20, 69). Moreover, JNK has been reported to activate Elk-1, resulting in an increase in c-fos gene expression (70). However, the proximal rPRL promoter does not contain ATF/CREB sites. Although the proximal rPRL promoter does not contain any consensus AP-1 sites (TGA(C/G)TCA) (71), it is conceivable that c-Jun could still be involved as a nuclear acceptor of a JNK signal. Therefore, we used dnJun to examine whether c-Jun might be involved as a nuclear acceptor of the JNK signal. DnJun has been characterized and successfully used for the derivative acts at a point distal to JNK in the JNK signal transduction cascade in a number of studies (72, 73). Co-transfection of a dnJun expression vector had no effect on the PrRP-induced rPRL promoter activation (data not shown), suggesting that c-Jun is not a substrate for JNK in the PrRP-induced rPRL promoter activation. By contrast, several putative Ets sites ((A/C)GGAA), located at positions 295, 185, and 165, are found in the rPRL promoter. Ets, which appears to mediate transcriptional responses to the ERK cascade, is an important component in the regulation of lactotroph-specific rPRL gene expression (74) and in the regulation of the rPRL promoter in response to Ras (27, 28), insulin (59, 60), insulin-like growth factor-1 (61), and fibroblast growth factor (62). These data suggest that activation of the ERK cascade leading to the phosphorylation of an Ets factor could be involved in the activation of the rPRL promoter by PrRP. Co-transfection with either pAPr-etsZ (Fig. 7A) or an pRK5-ets-21-328 (Fig. 7B) completely inhibited the PrRP-induced rPRL promoter activation. Moreover, the Ets-domain transcription factor Elk-1 is a substrate for both ERK and JNK (56). Thus, there is a possibility that PrRP might use both ERK and JNK cascades to elicit rPRL promoter activity with the Ets site as the responsible region.

The signaling cascades that couple the activation of PrRP receptor to transcription are not yet fully defined. Since G_i-mediated ERK activation is initiated by phosphatidylinositol 3-kinase activity (64) and wortmannin, an inhibitor of phosphatidylinositol 3-kinase, prevents the response of the rPRL promoter to insulin-like growth factor-1 (61), potential candidates for such cascades include those mediated by phosphatidylinositol 3-kinase. In addition, it remains to be determined whether other MAP kinase family members such as p38 or the newly described SAPK3 (22), are also activated by PrRP. Moreover, the complete role of the MAP kinase family in the action of PrRP in lactotrophs remains to be explored. Apart from a contribution to mediating transcriptional responses to PrRP, either ERK or JNK activation may be associated with other yet unknown cellular responses to PrRP, such as effects on long-term maintenance of the lactotroph phenotype.

	ACKNOWLEDGEMENTS

We thank Dr. A. Gutierrez-Hartmann for the gift of the reporter construct pA3-425PRLluc and the plasmid pLNCX-MAPK (K  M), Dr. E. Nishida for the gift of the plasmid pcDL-SR-SAPK-VPF, Dr. K. E. Boulukos for the gift of the plasmids encoding Ets-2 and its dominant negative form, Dr. M. Ostrowski for the gift of pAPr-etsZ, Dr. D. Mercola for the gift of the plasmid encoding the dominant negative c-Jun, Dr. Motoyoshi Sakaue for the gift of pEXV-Erk2-tag, and Dr. Kazushige Touhara for the gift of pRK and pRK-ARK1.

	FOOTNOTES

^* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom all correspondence and reprint requests should be addressed: Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Fax: 011-81-6-6879-3359; Tel.: 011-81-6-6879-3354; E-mail: masa@gyne.med.osaka-u.ac.jp.

	ABBREVIATIONS

The abbreviations used are: PRL, prolactin; PrRP, prolactin-releasing peptide; TRH, thyrotropin-releasing hormone; rPRL, rat prolactin; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated (protein) kinase; JNK, c-Jun N-terminal protein kinase; SAPK, stress-activated protein kinase; iMAPK, a catalytically inactive form of MAPK; dnJun, dominant negative c-Jun; MBP, myelin basic protein; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; PTX, pertussis toxin; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; BAPTA-AM, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester; DMEM, Dulbecco's modified Eagle's medium; CMV, cytomegalovirus; PKC, protein kinase C.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES